Biotech

All Articles

Lykos are going to ask FDA to reexamine its own selection complying with being rejected of MDMA treatment for trauma

.Complying with a bad revealing for Lykos Therapies' MDMA candidate for post-traumatic stress disord...

AN 2 halves census, quits phase 3 trial after data let down

.AN2 Rehabs is reconsidering its company in feedback to lackluster midphase records, vowing to lay o...

Merck pays for $700M for bispecific, snooping autoimmune position and chance to challenge Amgen in cancer cells

.Merck &amp Co. is paying $700 million beforehand to test Amgen in a blood cancer market. The bargai...

Gilead pays J&ampJ $320M to exit licensing bargain for seladelpar

.Along With Gilead Sciences about to an FDA selection for its own liver disease medication seladelpa...

' All hands on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can easily view the providers setting up camping tents at basec...

Entero giving up personnel, vacating workplace as well as stopping briefly R&ampD

.Mattress Liquidators has transformed Entero Therapies white colored as a slab. The lender ordered E...

Exelixis drops ADC after choosing it is actually no match for Tivdak

.Exelixis is actually losing hope on its cells variable (TF)- targeting antibody-drug conjugate afte...

Relay dislikes SHP2 inhibitor after Genentech leaves behind

.Three weeks after Roche's Genentech unit bowed out an SHP2 prevention pact, Relay Therapy has confi...

Stoke's Dravet syndrome med released of predisposed scientific grip

.Stoke Therapeutics' Dravet disorder medicine has been actually freed from a partial hold, clearing ...

Fierce Biotech's Gabrielle Masson provides Tough 15 at NYSE

.Ferocious Biotech Associate Editor Gabrielle Masson presented the 2024 class of Fierce 15 victors o...